Related references
Note: Only part of the references are listed.A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities
Ferdinando D'Amico et al.
JOURNAL OF CROHNS & COLITIS (2021)
Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment
Catherine Le Berre et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Modern use of 5-aminosalicylic acid compounds for ulcerative colitis
Catherine Le Berre et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Evolving therapeutic goals in ulcerative colitis: towards disease clearance
Silvio Danese et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Review article: faecal calprotectin and histologic remission in ulcerative colitis
Ferdinando D'Amico et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Positioning Therapies in Ulcerative Colitis
Silvio Danese et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Early Intervention in Ulcerative Colitis: Ready for Prime Time?
Virginia Solitano et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
Jean-Frederic Colombel et al.
JOURNAL OF CROHNS & COLITIS (2020)
The Role of Early Biologic Therapy in Inflammatory Bowel Disease
Dana Rachel Berg et al.
INFLAMMATORY BOWEL DISEASES (2019)
A current overview of corticosteroid use in active ulcerative colitis
Marco Salice et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2019)
Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis
Stefanos Bonovas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Ulcerative Colitis
Joseph D. Feuerstein et al.
MAYO CLINIC PROCEEDINGS (2019)
Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience
Giovanni Maconi et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2019)
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis
Silvio Danese et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2019)
Moving from efficacy to effectiveness: budesonide multimatrix in ulcerative colitis
Fernando Magro et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2019)
AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis
Siddharth Singh et al.
GASTROENTEROLOGY (2019)
AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis
Cynthia W. Ko et al.
GASTROENTEROLOGY (2019)
Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives
Nanne K. H. de Boer et al.
JOURNAL OF CROHNS & COLITIS (2018)
Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review
Mathurin Fumery et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Does Azathioprine induce endoscopic and histologic healing in pediatric inflammatory bowel disease? A prospective, observational study
Francesca Paola Giugliano et al.
DIGESTIVE AND LIVER DISEASE (2018)
Changing treatment paradigms for the management of inflammatory bowel disease
Jong Pil Im et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2018)
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study
Mariangela Allocca et al.
JOURNAL OF CROHNS & COLITIS (2018)
Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis
Belinda Jackson et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2018)
Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART approach
Silvio Danese et al.
INTESTINAL RESEARCH (2018)
Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study
Mary Kaye Willian et al.
JOURNAL OF PATIENT-REPORTED OUTCOMES (2018)
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses
Nghia H. Nguyen et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis
Stefanos Bonovas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology
Cristina Bezzio et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2017)
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
David T. Rubin et al.
JOURNAL OF CROHNS & COLITIS (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2017)
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis
G. R. D'Haens et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis
G. Roda et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2016)
Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
L. Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis
Roberta Pica et al.
DIGESTIVE AND LIVER DISEASE (2015)
Budesonide MMX®: A Review of Its Use in Patients with Mild to Moderate Ulcerative Colitis
Sheridan M. Hoy
DRUGS (2015)
Ulcerative Colitis Care Pathway
Themistocles Dassopoulos et al.
GASTROENTEROLOGY (2015)
Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
Gary R. Lichtenstein et al.
JOURNAL OF CROHNS & COLITIS (2015)
IBD-related work disability in the community: Prevalence, severity and predictive factors. A cross-sectional study
Alexis Ramos et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2015)
Clinical Predictors of Colectomy in Patients with Ulcerative Colitis: Systematic Review and Meta-analysis of Cohort Studies
Claudia Camila Dias et al.
JOURNAL OF CROHNS & COLITIS (2015)
Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study
Anders Lasson et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2015)
Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis
Mark T. Osterman et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
Simon P. L. Travis et al.
GUT (2014)
eHealth: Individualization of Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis
Natalia Pedersen et al.
INFLAMMATORY BOWEL DISEASES (2014)
Ulcerative colitis-associated colorectal cancer
Masakazu Yashiro
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis
B. Flourie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease
J. R. Goodhand et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Histologic Markers of Inflammation in Patients With Ulcerative Colitis in Clinical Remission
Laura Rosenberg et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases: A Systematic Review
Anthony Lopez et al.
INFLAMMATORY BOWEL DISEASES (2013)
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis
Debanjali Mitra et al.
BMC GASTROENTEROLOGY (2012)
Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects?
Chiara De Cassan et al.
DIGESTIVE DISEASES (2012)
Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis
Brian G. Feagan et al.
INFLAMMATORY BOWEL DISEASES (2012)
Strategies in maintenance for patients receiving long-term therapy (SIMPLE): A study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis
Sunanda Kane et al.
INFLAMMATORY BOWEL DISEASES (2012)
Adherence of gastroenterologists to European Crohn's and Colitis Organisation Consensus on Crohn's disease: A real-life survey in Spain
J. Hinojosa et al.
JOURNAL OF CROHNS & COLITIS (2012)
Current misunderstandings in the management of ulcerative colitis
Thomas Ochsenkuhn et al.
GUT (2011)
Impact of a Tailored Patient Preference Intervention in Adherence to 5-Aminosalicylic Acid Medication in Ulcerative Colitis: Results from an Exploratory Randomized Controlled Trial
Tetyana Moshkovska et al.
INFLAMMATORY BOWEL DISEASES (2011)
Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study
Nobuo Hiwatashi et al.
JOURNAL OF GASTROENTEROLOGY (2011)
New Drug Delivery Systems in Inflammatory Bowel Disease: MMX™ and Tailored Delivery to the Gut
G. Fiorino et al.
CURRENT MEDICINAL CHEMISTRY (2010)
Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2010)
Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: A real-life survey in Spain
J. P. Gisbert et al.
JOURNAL OF CROHNS & COLITIS (2010)
Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis
Axel U. Dignass et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis
A. Buckland et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Review article: medication non-adherence in ulcerative colitis - strategies to improve adherence with mesalazine and other maintenance therapies
A. B. Hawthorne et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Budesonide: Teaching an Old Dog New Tricks for Inflammatory Bowel Disease Treatment
Erika Angelucci et al.
CURRENT MEDICINAL CHEMISTRY (2008)
MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis
Mary Y. Hu et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Risk factors for non-adherence to medication in inflammatory bowel disease patients
R. D'Inca et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial
Stephen B. Hanauer et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2007)
Effect of weekend 5-aminosalicylic acid (Mesalazine) enema as maintenance therapy for ulcerative colitis: Results from a Randomized controlled study
Hiroshi Yokoyama et al.
INFLAMMATORY BOWEL DISEASES (2007)
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
Gary R. Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis
Michael A. Kamm et al.
GASTROENTEROLOGY (2007)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Systematic review: adherence issues in the treatment of ulcerative colitis
SV Kane
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial
SB Hanauer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease
AP Kennedy et al.
GUT (2004)
Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease
MJ Shale et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Medication Nonadherence and the outcomes of patients with quiescent ulcerative colitis
S Kane et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial
P Paoluzi et al.
DIGESTIVE AND LIVER DISEASE (2002)
Share Paper
